Riociguat could improve the exercise capacity and residual symptoms in patients with chronic
thromboembolic pulmonary hypertension (CTEPH) even after normalization of pulmonary arterial
pressure by balloon pulmonary angioplasty (BPA). This randomized controlled trial study aimed
to clarify whether the improvement of peak cardiac index (CI) during exercise maintains or
not between the riociguat continued group and the riociguat discontinued group.
Phase:
Phase 2
Details
Lead Sponsor:
National Hospital Organization Okayama Medical Center